16th Annual Scientific Meeting - Heart Failure Society of America

Presenter/Planner Disclosure Information
2012 Abstract Reviewers
The Heart Failure Society of America has a disclosure policy that
requires oral presenters to disclose whether or not they have relevant
financial relationships with any commercial interest and whether or
not off-label or investigational drug/device use will be discussed.
All oral and poster presenters’ disclosure information received is
listed in the HFSA Presenter/Author Disclosure Booklet . A booklet
is in each meeting congress bag. In addition, each oral presenter will
have a disclosure slide at the beginning of his/her presentation.
Scientific Program Learning Objectives
Following this meeting, participants will be able to:
1. Describe the epidemiology of HF, including environmental factors,
and implement strategies for the prevention of HF.
2. Describe current knowledge about the scientific basis of HF at the
levels of cardiovascular physiology, neurohormones, tissue factors,
and molecular biology and genetics.
3. Identify the findings of basic science and current clinical trials and
their implications for current and future HF therapy.
4. Implement optimal guideline-based therapeutic options for HF,
including pharmacologic agents, non-pharmacologic options, such
as diet and exercise; and devices.
5. Manage comorbidities including hypertension, diabetes, and
cognitive issues.
6. Demonstrate awareness of psychosocial, economic and ethical
issues in the treatment of patients with HF.
7. Implement strategies for effective management of the patient with
HF, incorporating the family, encouraging self-care, and employing
the medical home model.
8. Outline strategies for transitioning patients from impatient to
outpatient and for reducing hospital readmissions.
9. Engage in performance measurement and other site-based research.
10. Outline strategies for more effective communication with patients,
families, and other health professionals.
Scientific Session and Satellite Symposia learning objectives are listed
at the end of each session in the program book.
Nancy M. Albert, RN, PhD
Cleveland, OH
Larry A. Allen, MD, MHS
Denver, CO
Mark E. Anderson, MD, PhD
Iowa City, IA
J. Malcolm O. Arnold, MD
London, ON, Canada
Burns C. Blaxall, PhD
Cincinnati, OH
Guido Boerrigter, MD
Rochester, MN
Biykem Bozkurt, MD
Houston, TX
Harleah G. Buck, RN, PhD, CHPN
University Park, PA
Javed Butler, MD, MPH
Atlanta, GA
Horng H. Chen, MBBCh
Rochester, MN
James P. Daubert, MD
Durham, NC
Teresa De Marco, MD
San Francisco, CA
Prakash C. Deedwania, MD
Fresno, CA
David DeNofrio, MD
Boston, MA
Akshay S. Desai, MD
Boston, MA
Anita Deswal, MD, MPH
Houston, TX
Mark H. Drazner, MD
Dallas, TX
Justin A. Ezekowitz, MBBCh
Edmonton, AB, Canada
James C. Fang, MD
Cleveland, OH
G. Michael Felker, MD
Durham, NC
Jalal K. Ghali, MD
Detroit, MI
Michael M. Givertz, MD
Boston, MA
Joshua I. Goldhaber, MD
Los Angeles, CA
Steven Goldman, MD
Tucson, AZ
Roger J. Hajjar, MD
New York, NY
Paul A. Heidenreich, MD, MS
Palo Alto, CA
Adrian F. Hernandez, MD
Durham, NC
Ray E. Hershberger, MD
Columbus, OH
J. Thomas Heywood, MD
La Jolla, CA
Tamara B. Horwich, MD
Los Angeles, CA
Steven R. Houser, PhD
Philadelphia, PA
Corrine Y. Jurgens, RN, PhD
Miller Place, NY
David E. Lanfear, MD, MS
Detroit, MI
Christopher S. Lee, RN, PhD
Portland, OR
Terry A. Lennie, PhD, MS
Lexington, KY
Annarosa Leri, MD
Boston, MA
Ronglih Liao, PhD
Boston, MA
JoAnn Lindenfeld, MD
Denver, CO
Kenneth B. Margulies, MD
Philadelphia, PA
Paul J. Mather, MD
Philadelphia, PA
Dennis M. McNamara, MD
Pittsburgh, PA
Alan B. Miller, MD
Jacksonville, FL
Judith E. Mitchell, MD
New York, NY
Jeffery D. Molkentin, PhD
Cincinnati, OH
12 13